Dr. Amber L. Flaherty, MD

Dr. Flaherty practices at American Oncology Partners PA in Phoenix, Arizona.

Dr. Flaherty's NPI, 1093008336, was assigned on May 19, 2011. Dr. Flaherty graduated from St. George's University School of Medicine in 2008. Dr. Flaherty holds Arizona license 50181.

Dr. Flaherty's primary practice is American Oncology Partners PA, at 11209 N Tatum Blvd, Phoenix, AZ 85028 in Maricopa County. The practice phone is (614) 383-6000.

Dr. Flaherty's primary practice is American Oncology Partners PA in Phoenix, Arizona. Dr. Flaherty is also affiliated with City of Hope Cancer Center Phoenix. The medical group on file is City of Hope. Dmand AI also links Dr. Flaherty to 1 more hospital, 1 group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Flaherty practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Flaherty's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Flaherty is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Flaherty's licenses on file in 3 states: Arizona, Florida and Texas.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Flaherty treats.

CMS data shows 14,805 Medicare services from Dr. Flaherty across 31 procedure codes in 2024, for 355 Medicare patients. Medicare paid $325,042 for them. Every service was in an office.

CMS counts 355 Medicare patients who saw Dr. Flaherty in 2024. The largest group is 65 to 74, with 163 patients. 69% of them have high cholesterol, and 64% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Flaherty's median patient age at 73, with 46% women.

In 2024, Dr. Flaherty wrote 1,467 Medicare Part D claims for 199 patients. 70% of them were for generic drugs. CMS names the drug for 1,214 of them, across 46 drugs with 11 or more claims each, at $2,552,006 in total drug cost. In 2023, CMS named 1,332 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Flaherty for performance year 2024, reported as part of a group. Dr. Flaherty accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Flaherty as offering telehealth.

Dmand AI links 9 papers to Dr. Flaherty, published from 2011 to 2024. 2013 was the busiest year, with 5. The most frequent topics are Carcinoma, Renal Cell, Everolimus and Kidney Neoplasms. Dr. Flaherty has published most often in Clin Genitourin Cancer. Dr. Flaherty's most frequent co-authors are Dathan Hamann, MD, Eric Jonasch, MD and Guy Christopher Charest, DO.

CMS Open Payments shows 1,229 general payments to Dr. Flaherty from 87 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 51% of the total. Global Blood Therapeutics, Inc. paid the most, $11,791.

Dr. Flaherty graduated from St. George's University School of Medicine in 2008.

Dr. Flaherty is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.